EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test

Sean Apap Mangion iD, Charles Wade iD, Tom Williams iD, Alessia Bianchi, Floriana De Angelis, Sarah Wright iD, Nevin John iD, Anisha Doshi, Alberto Calvi, Obioma Oraluzume, Maya Leibowitz, Guglielmo Vecchio und 7 weitere

Brain and Behavior · 2025-12 · 15 (12)

DOI: 10.1002/brb3.71101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 26.11.2025. Verfasst von Sean Apap Mangion und 18 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, Universi…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Multiple Sclerosis, Chronic Progressive, Upper Extremity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Multiple Sclerosis Society - UK, National Multiple Sclerosis Society - US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9‐hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND‐23 is a well‐validated patient‐reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large‐scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.

Objectives

We sought to (van Munster et al. 2023) assess the associations between the ABILHAND‐23 and 9HPT, and (Huertas‐Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND‐23 scores, using baseline data from the MS‐STAT2 trial, a phase 3 study on simvastatin for secondary progressive MS (SPMS).

Methods

A cross‐sectional analysis of baseline data from the UCLH cohort of the MS‐STAT2 trial was performed using multiple linear regression to predict ABILHAND‐23 logit scores by 9HPT.

Results

225 participants were analyzed. ABILHAND‐23 scores moderately correlated with the 9HPT (rho = 0.47). Regression analysis showed that better 9HPT performance modestly predicted ABILHAND‐23 logits (β = –0.05, SE 0.008, p ‐value < 0.001).

Conclusion

The 9HPT only modestly predicts the ABILHAND‐23 but does not fully capture the individual's daily disability experience, underscoring the value of patient‐reported outcome measures (PROMs) like the ABILHAND‐23 in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresMultiple Sclerosis, Chronic ProgressiveUpper ExtremityHumansCross-Sectional StudiesMaleMiddle AgedFemaleAdultDisability EvaluationActivities of Daily Living

Stichwörter der Autor:innen

PROMsclinical trialsoutcome measuresprogressive

Autor:innen und Institutionen

  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia.
  • Department of Neurology, Monash Health, Clayton, Australia.
  • Comprehensive Clinical Trials Unit, University College London, London, UK.
  • Department of Statistics, Institute of Child Health, University College London, London, UK.
  • London School of Hygiene and Tropical Medicine Centre of Global Change and Health, Medical Statistics, London, UK.

ORCID-Profile: Sean Apap Mangion, Charles Wade, Tom Williams, Sarah Wright, Nevin John

Förderung

  • National Institute for Health and Care Research
  • Multiple Sclerosis Society - UK
  • National Multiple Sclerosis Society - US
  • Rosetrees Trust

Zitieren

APA

Apap Mangion, S., Wade, C., Williams, T., Bianchi, A., Angelis, F., Wright, S., John, N., Doshi, A., Calvi, A., Oraluzume, O., Leibowitz, M., Vecchio, G., Blackstone, J., Braisher, M., Favarato, G., Nicholas, J., Farrell, R., Chataway, J., & UCL MS‐STAT2 Investigators (2025). The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test. Brain and Behavior, 15(12). https://doi.org/10.1002/brb3.71101

Vancouver

Apap Mangion S, Wade C, Williams T, Bianchi A, Angelis F, Wright S, et al. The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test. Brain and Behavior. 2025;15(12). doi:10.1002/brb3.71101

BibTeX
@article{ApapMangion2025,
  author = {Apap Mangion, Sean and Wade, Charles and Williams, Tom and Bianchi, Alessia and Angelis, Floriana De and Wright, Sarah and John, Nevin and Doshi, Anisha and Calvi, Alberto and Oraluzume, Obioma and Leibowitz, Maya and Vecchio, Guglielmo and Blackstone, James and Braisher, Marie and Favarato, Graziella and Nicholas, Jennifer and Farrell, Rachel and Chataway, Jeremy and UCL MS‐STAT2 Investigators, UCL MS‐STAT2 Investigators},
  title = {The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test},
  journal = {Brain and Behavior},
  year = {2025},
  volume = {15},
  number = {12},
  doi = {10.1002/brb3.71101}
}
Kostenlos starten →